selegiline ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
monoamine oxydase (MAO)-inhibitors type B 2429 14611-51-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • selegiline
  • (-)-deprenil
  • (-)-deprenyl
  • (-)-selegiline
  • (r)-(-)-deprenyl
  • (r)-selegiline
  • anipryl
  • l-deprenyl
  • selegina
  • selgene
  • zelapar
  • selegiline hydrochloride
  • selegiline HCl
A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.
  • Molecular weight: 187.29
  • Formula: C13H17N
  • CLOGP: 2.84
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 0
  • TPSA: 3.24
  • ALOGS: -3.87
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.89 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 4.40 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.13 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 5, 1989 FDA SOMERSET

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site rash 181.48 27.41 35 1661 2388 56287983
Application site erythema 170.27 27.41 37 1659 4563 56285808
Application site pruritus 99.12 27.41 23 1673 3796 56286575
Application site reaction 90.52 27.41 16 1680 670 56289701
Dyskinesia 80.67 27.41 31 1665 29077 56261294
Application site urticaria 75.97 27.41 12 1684 250 56290121
Hallucination 74.34 27.41 34 1662 49115 56241256
Hallucination, visual 68.37 27.41 24 1672 17444 56272927
Parkinsonism hyperpyrexia syndrome 67.96 27.41 10 1686 127 56290244
Application site irritation 59.45 27.41 13 1683 1639 56288732
Drug interaction 36.79 27.41 38 1658 209717 56080654
Application site pain 30.14 27.41 9 1687 3911 56286460
Impulse-control disorder 27.74 27.41 6 1690 717 56289654
Delusion 27.68 27.41 11 1685 11204 56279167

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 161.72 29.13 76 2341 46334 31648593
Dyskinesia 127.83 29.13 51 2366 20859 31674068
Hallucination, visual 87.77 29.13 36 2381 15758 31679169
Impulse-control disorder 86.69 29.13 20 2397 1256 31693671
Hypersexuality 84.59 29.13 20 2397 1398 31693529
Gambling disorder 77.09 29.13 19 2398 1583 31693344
Dopamine dysregulation syndrome 73.90 29.13 14 2403 332 31694595
Application site rash 68.14 29.13 15 2402 761 31694166
On and off phenomenon 67.14 29.13 18 2399 2092 31692835
Delusion 62.07 29.13 26 2391 11971 31682956
Application site erythema 44.18 29.13 13 2404 2116 31692811
Parkinsonism hyperpyrexia syndrome 41.67 29.13 7 2410 81 31694846
Binge eating 32.74 29.13 6 2411 118 31694809
Impulsive behaviour 31.94 29.13 10 2407 2003 31692924
Orthostatic hypotension 29.64 29.13 20 2397 24099 31670828

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 179.90 24.75 83 3354 76177 70848830
Application site rash 165.36 24.75 34 3403 1975 70923032
Dyskinesia 164.17 24.75 65 3372 41009 70883998
Hallucination, visual 151.58 24.75 56 3381 29281 70895726
Application site erythema 131.17 24.75 33 3404 4728 70920279
Parkinsonism hyperpyrexia syndrome 107.59 24.75 17 3420 214 70924793
Impulse-control disorder 101.35 24.75 22 3415 1657 70923350
Gambling disorder 87.38 24.75 20 3417 1918 70923089
Hypersexuality 86.10 24.75 19 3418 1544 70923463
Dopamine dysregulation syndrome 75.37 24.75 14 3423 476 70924531
Delusion 75.31 24.75 30 3407 19135 70905872
Application site pruritus 61.06 24.75 17 3420 3584 70921423
Application site urticaria 50.74 24.75 9 3428 235 70924772
Application site irritation 43.48 24.75 11 3426 1606 70923401
Parkinson's disease 42.34 24.75 11 3426 1784 70923223
On and off phenomenon 42.00 24.75 12 3425 2774 70922233
Muscle rigidity 36.80 24.75 18 3419 18632 70906375
Application site reaction 35.49 24.75 8 3429 715 70924292
Orthostatic hypotension 35.07 24.75 25 3412 51718 70873289
Drug interaction 31.80 24.75 62 3375 381379 70543628
Sudden onset of sleep 31.12 24.75 7 3430 620 70924387
Insomnia 30.98 24.75 45 3392 217761 70707246
Psychotic disorder 29.74 24.75 20 3417 37681 70887326
Sleep talking 27.59 24.75 7 3430 1034 70923973
Binge eating 27.26 24.75 6 3431 481 70924526
Tremor 26.38 24.75 35 3402 155589 70769418
Choking 25.86 24.75 12 3425 11048 70913959
Agitation 25.83 24.75 27 3410 93348 70831659
Marital problem 25.68 24.75 5 3432 219 70924788
Application site pain 24.91 24.75 9 3428 4393 70920614
Impulsive behaviour 24.89 24.75 8 3429 2746 70922261
Pneumonia aspiration 24.77 24.75 22 3415 62267 70862740

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N04BD01 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Monoamine oxidase B inhibitors
FDA MoA N0000000184 Monoamine Oxidase Inhibitors
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000928 Antidepressive Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D008996 Monoamine Oxidase Inhibitors
MeSH PA D018696 Neuroprotective Agents
MeSH PA D020011 Protective Agents
MeSH PA D011619 Psychotropic Drugs
CHEBI has role CHEBI:176497 geroprotectors
CHEBI has role CHEBI:38623 monoamine oxidase inhibitors
CHEBI has role CHEBI:48407 antiparkinson agent
CHEBI has role CHEBI:48560 dopaminergic agents
FDA EPC N0000175744 Monoamine Oxidase Inhibitor
FDA MoA N0000175761 Monoamine Oxidase-B Inhibitors
FDA EPC N0000175762 Monoamine Oxidase Type B Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Parkinson's disease indication 49049000 DOID:14330
Major depressive disorder indication 370143000
Suicidal thoughts contraindication 6471006
Bipolar disorder contraindication 13746004 DOID:3312
Orthostatic hypotension contraindication 28651003
Conduction disorder of the heart contraindication 44808001
Psychotic disorder contraindication 69322001
Kidney disease contraindication 90708001 DOID:557
Tardive dyskinesia contraindication 102449007
Angina pectoris contraindication 194828000
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Pheochromocytoma contraindication 302835009
Malignant melanoma contraindication 372244006




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Cognitive dysfunction syndrome (CDS) Indication
Dogs Pituitary dependent hyperadrenocorticism (PDH) Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Anipryl Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.6 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Amine oxidase [flavin-containing] B Enzyme INHIBITOR Ki 7.26 CHEMBL CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 6.76 DRUG MATRIX
Amine oxidase [flavin-containing] A Enzyme Ki 5.04 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.17 DRUG MATRIX
Alpha-synuclein Transporter IC50 6.57 CHEMBL
Amine oxidase [flavin-containing] B Enzyme Ki 5.87 CHEMBL
Amine oxidase [flavin-containing] A Enzyme Ki 4.98 CHEMBL
Amine oxidase [flavin-containing] A Enzyme Ki 5.42 CHEMBL
Amine oxidase [flavin-containing] B Enzyme Ki 6.01 CHEMBL
Monoamine oxidase Enzyme IC50 7.89 CHEMBL

External reference:

IDSource
4019929 VUID
N0000148014 NUI
D00785 KEGG_DRUG
14611-52-0 SECONDARY_CAS_RN
4019485 VANDF
4019929 VANDF
C0036579 UMLSCUI
CHEBI:50217 CHEBI
CHEMBL972 ChEMBL_ID
DB01037 DRUGBANK_ID
CHEMBL1200904 ChEMBL_ID
D012642 MESH_DESCRIPTOR_UI
26757 PUBCHEM_CID
4436 INN_ID
6639 IUPHAR_LIGAND_ID
2K1V7GP655 UNII
203137 RXNORM
1551 MMSL
21238 MMSL
53269 MMSL
5448 MMSL
63129 MMSL
d00976 MMSL
003465 NDDF
004599 NDDF
108466000 SNOMEDCT_US
108467009 SNOMEDCT_US
372497003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZELAPAR HUMAN PRESCRIPTION DRUG LABEL 1 0187-0453 TABLET, ORALLY DISINTEGRATING 1.25 mg ORAL NDA 25 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-737 CAPSULE 5 mg ORAL ANDA 20 sections
Selegiline Hydrochloride Human Prescription Drug Label 1 16571-659 CAPSULE 5 mg ORAL ANDA 19 sections
EMSAM HUMAN PRESCRIPTION DRUG LABEL 1 49502-900 PATCH 6 mg TRANSDERMAL NDA 31 sections
EMSAM HUMAN PRESCRIPTION DRUG LABEL 1 49502-901 PATCH 9 mg TRANSDERMAL NDA 31 sections
EMSAM HUMAN PRESCRIPTION DRUG LABEL 1 49502-902 PATCH 12 mg TRANSDERMAL NDA 31 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-2918 TABLET 5 mg ORAL ANDA 19 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60429-176 TABLET 5 mg ORAL ANDA 20 sections
SELEGILINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 60505-0055 CAPSULE 5 mg ORAL ANDA 13 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60505-3438 TABLET 5 mg ORAL ANDA 20 sections
SELEGILINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 68151-2649 CAPSULE 5 mg ORAL ANDA 19 sections
Selegiline Hydrochloride Human Prescription Drug Label 1 70954-504 CAPSULE 5 mg ORAL ANDA 20 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71205-888 CAPSULE 5 mg ORAL ANDA 19 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71205-888 CAPSULE 5 mg ORAL ANDA 19 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 72319-006 TABLET 5 mg ORAL ANDA 15 sections